ANAB · CIK 0001370053
What AnaptysBio, Inc. told the SEC could break it.
2 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
A limited set so far, we surface every cited disclosure we’ve extracted for ANAB. More may follow as additional filings are processed.
In its own words
What could break it.
Climate & physical
- San Diego facilities — seismic / wildfire / blackoutmedium
All facilities sit in San Diego, a seismically active region historically subject to wildfires and electrical blackouts from power shortages.
“Our facilities are located in San Diego, California, which is a seismically active region, and has also historically been subject to wildfires and electrical blackouts as a result of a shortage of available electrical power.”
SEC filing →As of 2026
Regulatory & policy
- US pharma tariffs on China-sourced ingredients (Section 232)medium
Pharmaceutical ingredients partially sourced from outside the US, including China, face rising costs from new tariff rates and an ongoing Section 232 investigation into pharma imports.
“Our products involve pharmaceutical ingredients that are partially sourced from outside of the United States, including China, the cost of which may increase due to additional tariff rates.”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“Under GSK Amendment No. 3, we were granted increased royalties upon sales of Jemperli, equal to 8% of net sales (as defined in the GSK Agreement) below $1.0 billion, 12% of net sales between $1.0 billion and $1.5 billion, 20% of net sales between $1.5 billion and $2.5 billion and 25% of net sales above $2.5 billion.”
Cited →“we made an upfront payment of $10.0 million to Anaptys and an additional $5.0 million for drug supply. Anaptys is eligible to receive future payments based upon achievement of specified regulatory approval and commercialization milestones as well as a 10% royalty on global net sales.”
Cited →“Pursuant to the terms of the Vanda License Agreement, we received an upfront payment of $ 10.0 million for the license and a $ 5.0 million payment for existing drug supply.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch